Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complement Inhibition After Subarachnoid Hemorrhage (C1-INH) Phase II Trial
2020-005731-67Phase 2Active
- Sponsor
- Haaglanden Medical Centre
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing C1-INH 6000 IU with Placebo (2 arms). Primary endpoint: Primary safety and efficacy of C1-INH 6000 IU. Started Mar 2021; status: active.
02
Drugs
C1 inhibitor, human
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2020-005731-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005731-67.